Conditions: SURMOUNT-3 · tirzepatide.
The figures are clear enough; the question is what they mean and what they do not.
I can supply the numbers if the specifics change the answer.
What can I legitimately conclude from this figure?
Whatever its primary endpoint was, at the power it was designed for, in the population it recruited — and nothing else. SURMOUNT-3 was sized to answer one question. Every other result in it is a secondary or exploratory endpoint, powered incidentally if at all, and a nominally significant secondary in a programme with twenty of them is what you would expect from chance alone. So the reading order is: primary endpoint, then whether the secondaries were pre-specified and hierarchically tested, then everything else as hypothesis-generating. A trial establishes one thing well and suggests several things badly, and the press coverage inverts that ranking reliably.
Before comparing two trials, check whether they share an endpoint definition. Frequently they do not, and the numbers then are not comparable in any sense.
Trial populations are selected. Exclusion criteria in this class routinely remove people with significant renal impairment, prior pancreatitis and unstable psychiatric illness, which is exactly the population the results are then quoted for.
Duration decides what can be seen. A 68-week trial can measure weight and glycaemia; it cannot measure anything whose event rate is one per cent per year without enrolling tens of thousands.
Where a result is quoted from a conference abstract rather than a peer-reviewed publication, the numbers routinely move between the two. It is worth checking which one you are reading.
Quote the interval alongside the estimate and half the disagreements on this site would not start.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe short version: the effect is real, the magnitude depends on the population, and the population is usually the part that gets dropped when a result is quoted second-hand.
A composite endpoint is only as informative as its least serious component. Where a cardiovascular composite combines death, infarction and stroke, ask which component moved, because they are not interchangeable outcomes.
To be exact about it, open-label extensions are not the same evidence as the randomised phase. Once everyone knows what they are taking, the reported outcomes acquire a bias that no analysis fully removes.
The cardiovascular outcome programme in this class runs to several large randomised trials — LEADER for liraglutide, SUSTAIN-6 and SELECT for semaglutide, REWIND for dulaglutide — and they are the reason the class is discussed as more than a weight intervention.
Read the protocol and the statistical analysis plan if the result matters to you. Both are usually published alongside.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.